Hormonal
Astragaloside IV (AS-IV), a saponin in Astragalus, reduces blood glucose and insulin resistance by modulating intestinal microbiota to increase butyric acid and activating PI3K/AKT and AMPK/SIRT1 signaling pathways.
Astragaloside IV (AS-IV), a key compound in Astragalus, may help lower blood sugar and improve insulin sensitivity. It works by changing gut bacteria to produce more butyric acid and by activating specific cellular pathways that help cells use insulin better. This suggests Astragalus may be beneficial for managing T2DM.
AS modulates the type and number of intestinal microbiota and increases butyric acid levels in diabetic mice (67). AS treatment of diabetes was found to be achieved by modulating two signaling pathways, PI3K/AKT and AMPK/SIRT1...
Why this rating
Based on rat and cell studies; no human clinical trials reported.
Source
Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review
Su Min et al. · Frontiers in Immunology · 2023
DOI 10.3389/fimmu.2023.1243834
More from this paper
- Astragalus improves intestinal barrier function and immunity by modulating intestinal microbiota, thereby treating Type 2 Diabetes Mellitus (T2DM).Moderate
- Astragalus polysaccharides (APS) improve T2DM outcomes by increasing the abundance of beneficial bacteria (e.g., Bifidobacterium, Lactobacillus) and short-chain fatty acids (SCFAs), while reducing insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →